Analysts Set Phibro Animal Health Corporation (NASDAQ:PAHC) Target Price at $42.50

Phibro Animal Health Corporation (NASDAQ:PAHC) has received a consensus rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $42.50.

Several research analysts recently issued reports on the stock. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Citigroup cut their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Finally, Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th.

Phibro Animal Health Stock Down 1.3%

Shares of NASDAQ:PAHC opened at $31.40 on Friday. Phibro Animal Health has a 52-week low of $25.34 and a 52-week high of $60.08. The firm has a fifty day moving average of $37.81 and a 200 day moving average of $43.97. The firm has a market capitalization of $1.27 billion, a PE ratio of 13.48, a price-to-earnings-growth ratio of 0.48 and a beta of 0.46. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The company had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, research analysts anticipate that Phibro Animal Health will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd were given a $0.12 dividend. The ex-dividend date was Wednesday, June 3rd. This represents a $0.48 annualized dividend and a yield of 1.5%. Phibro Animal Health’s payout ratio is 20.60%.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the completion of the transaction, the chief executive officer directly owned 67,720 shares in the company, valued at approximately $3,778,776. The trade was a 9.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,768 shares of company stock valued at $2,560,222 in the last ninety days. 50.13% of the stock is currently owned by insiders.

Institutional Trading of Phibro Animal Health

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Phibro Animal Health by 1,730.9% during the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after acquiring an additional 225,110 shares during the last quarter. Citigroup Inc. raised its stake in shares of Phibro Animal Health by 112.3% during the third quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock valued at $2,223,000 after acquiring an additional 29,066 shares during the last quarter. Precision Wealth Strategies LLC bought a new position in shares of Phibro Animal Health during the fourth quarter valued at about $1,568,000. Capricorn Fund Managers Ltd raised its stake in shares of Phibro Animal Health by 45.1% during the first quarter. Capricorn Fund Managers Ltd now owns 267,045 shares of the company’s stock valued at $14,770,000 after acquiring an additional 82,944 shares during the last quarter. Finally, Horizon Investment Services LLC raised its stake in shares of Phibro Animal Health by 241.3% during the fourth quarter. Horizon Investment Services LLC now owns 33,241 shares of the company’s stock valued at $1,242,000 after acquiring an additional 23,501 shares during the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.